➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Merck
Dow
Boehringer Ingelheim
Moodys

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR THRIVE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Thrive

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001262 ↗ Copper Histidine Therapy for Menkes Diseases Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 1/Phase 2 1990-06-01 Menkes Disease is a genetic disorder affecting the metabolism of copper. Patient with this disease are both physically and mentally retarded. Menkes disease is usually first detected in the first 2-3 months of life. Infant males born with the disease fail to thrive, experience hypothermia, have delayed development, and experience seizures. These infants also have characteristic physical features such as changes of their hair and face. Females may also have changes in hair and skin color, but rarely have significant medical problems. Appropriate treatment of Menkes Disease requires that the disease be diagnosed early and treatment started before irreversible brain damage occurs. The aim of treatment is to bypass the normal route of absorption of copper through the gastrointestinal tract. Copper must then be delivered to brain cells and be available for use by enzymes. Copper histidine is a copper replacement that can be injected directly into the body to avoid absorption through the gastrointestinal tract. However, studies have shown the genetic abnormalities causing Menkes disease cannot simply be corrected by copper replacement injections. The genetic abnormality causing Menkes disease can vary in its severity. Patients with a genetic abnormality that may still permit some production of the enzymes required to process copper may receive benefit from early treatment with copper replacement. However, patients with severe abnormalities of the genes responsible for copper metabolism may receive no benefit from copper replacement. The purpose of this study is to continue to evaluate the effects of early copper histidine in Menkes disease patients and to correlate specific molecular defects with responses to treatment.
NCT00002182 ↗ A Study of Megestrol Acetate in HIV-Infected Children Completed Gamma Project - ACTU N/A 1969-12-31 The purpose of this study is to see if megestrol acetate is safe and effective in treating HIV-infected children with failure to thrive (FTT).
NCT00006401 ↗ Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 2000-09-01 To determine whether or not inhaled nitric oxide (iNO) safely decreases the incidence of chronic lung disease (CLD) in premature infants.
NCT00006401 ↗ Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants Completed University of Colorado, Denver Phase 3 2000-09-01 To determine whether or not inhaled nitric oxide (iNO) safely decreases the incidence of chronic lung disease (CLD) in premature infants.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Thrive

Condition Name

Condition Name for Thrive
Intervention Trials
Furunculosis 2
Staphylococcus Aureus 2
Obstructive Sleep Apnea 2
Malnutrition 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Thrive
Intervention Trials
Sleep Apnea, Obstructive 3
Sleep Apnea Syndromes 3
Apnea 3
Abscess 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Thrive

Trials by Country

Trials by Country for Thrive
Location Trials
United States 74
France 6
Italy 5
United Kingdom 4
Canada 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Thrive
Location Trials
California 8
Texas 7
Missouri 6
Ohio 5
North Carolina 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Thrive

Clinical Trial Phase

Clinical Trial Phase for Thrive
Clinical Trial Phase Trials
Phase 4 8
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Thrive
Clinical Trial Phase Trials
Completed 13
Not yet recruiting 11
Recruiting 7
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Thrive

Sponsor Name

Sponsor Name for Thrive
Sponsor Trials
Washington University School of Medicine 2
University Hospital, Toulouse 2
University of Texas Southwestern Medical Center 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Thrive
Sponsor Trials
Other 55
Industry 13
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.